Abraxis BioScience, Inc. (NASDAQ:ABII) presented abstracts describing 10 trials of n anoparticle a lbumin b ound ( nab ®) driven chemotherapy, nab-paclitaxel (ABRAXANE ® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Studies included three ongoing trials of nab-paclitaxel in the treatment of triple-negative breast cancer (TNBC), HER2-negative primary operable breast cancer, and elderly patients with an increased risk for relapse of a primary carcinoma of the breast, continuing the company’s focus on developing treatments for difficult-to-treat cancers. ABRAXANE is currently approved for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Abraxis BioScience is currently investigating the potential of its propriety nab-driven chemotherapy as monotherapy or in combination across a wide-range of advanced and hard-to- treat cancers, including in metastatic and triple-negative breast cancer. nab-chemotherapy is thought to leverage a previously unrecognized tumor-activated, albumin-specific biologic pathway to activate an albumin-specific (Gp60) receptor-mediated transcytosis path through the cell wall of proliferating tumor cells and deliver targeted cytotoxic drugs to the tumor. “We continue to explore ABRAXANE’s utility to treat breast cancer with an emphasis on the more difficult-to-treat sub-groups such as triple negative disease,” said Patrick Soon-Shiong, M.D., Executive Chairman and founder of Abraxis BioScience. About the Studies I. Neoadjuvant bevacizumab with weekly nanoparticle albumin bound nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer. (Abstract #TPS100) In this phase 2 study, 60 patients with TNBC will be treated. Patients must be diagnosed with palpable and operable TNBC less than or equal to two centimeters.